Malignant Mesenchymal Tumor 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Malignant Mesenchymal Tumor
Li2CO3, NCT01669369: Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma

Recruiting
4
400
RoW
Lithium Carbonate, Lithobid, Placebo, PLACEBO TREATMENT
Sun Yat-sen University, Qilu Hospital of Shandong University, Nanfang Hospital of Southern Medical University, Shenzhen Second People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanghai 6th People's Hospital
Osteosarcoma
12/23
12/23
SSGXX, NCT00790244 / 2007-001152-39: A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall

Recruiting
2
188
Europe
doxorubicin , ifosfamide, Doxorubicin, Holoxan, doxorubicin, ifosfamide
Oslo University Hospital, Scandinavian Sarcoma Group
Soft Tissue Sarcoma, Non Metastatic Disease
10/12
10/22
NCT00436735: Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Active, not recruiting
1
45
US
midazolam hydrochloride, nelfinavir mesylate, gene expression analysis, polymerase chain reaction, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry
National Cancer Institute (NCI)
Colorectal Cancer, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Islet Cell Tumor, Lung Cancer, Metastatic Cancer, Neuroendocrine Carcinoma of the Skin, Ovarian Cancer, Pheochromocytoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

No Longer Available
N/A
US
Trabectedin, YONDELIS
University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Soft Tissue Sarcoma
 
 
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

No Longer Available
N/A
US, Canada, RoW
Trabectedin
Janssen Research & Development, LLC
Sarcoma
 
 

Download Options